Gilead commits millions more for HIV health equity efforts in southern cities

Beth Snyder Bulik

Senior Editor

The Covid-19 pandemic fanned the flames of health disparities across the US — but especially in the South, which was already suffering from higher rates of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead commits millions more for HIV health equity efforts in southern cities

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Gilead com­mits mil­lions more for HIV health eq­ui­ty ef­forts in south­ern cities

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Gilead commits millions more for HIV health equity efforts in southern cities

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront